Integration Is the New Compliance Currency
In 2026, compliance will hinge on RBQM integration, a governance loop that links risk with audit-ready evidence.
In 2026, compliance will hinge on RBQM integration, a governance loop that links risk with audit-ready evidence.
Partial RBQM implementation is a structural weakness that exposes sponsors to risk and regulatory scrutiny.
In 2026, global regulators will require RBQM in every stage of clinical trials.
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
As sponsors adapt to ICH R3, we explore whether sites are getting the support they need to keep up.
QbD is the most effective way to protect participants and data in clinical trials, yet the industry still struggles to make it a priority.
TRI’s GCP e-learning module turns ICH E6(R3) principles into practical, scenario-based training.
Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.